+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Next Generation Sequencing Kits Market: Distribution by Type of Nucleotide Sequenced, Type of End User and Key Geographies - Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 218 Pages
  • January 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557567
The field of genomic data collection and analysis has evolved significantly since the introduction of a gene sequencing method by Frederick Sanger in 1977. Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, parallel genome sequencing technology has greatly reduced the overall cost and time investment. In fact, compared to the Human Genome Project (~USD 3 billion), the cost of sequencing a single genome has decreased considerably (to USD 1,000), for currently available technologies. Given the ongoing innovation in this field, stakeholders further believe that, over the next decade, the aforementioned cost may further get reduced to USD 100. It is worth mentioning that this decrease in genome sequencing cost has led to an increase in the number of genomes being sequenced, across the globe. 

Despite the recent advances in the field of genomics, the nucleotide library preparation process is still marred with several challenges, including requirement of large amounts of input samples, low volume of yield and concerns related to quality of the product. In addition, the manual DNA library / RNA library preparation process is time consuming, requiring extensive manipulation and expensive reagents. Therefore, innovators in the pharmaceutical industry are constantly identifying / developing ways to improve the process of DNA library / RNA library preparation. Amidst other alternatives, the use of NGS library preparation kits has emerged as a viable option for various drug developers and academic / research institutes to overcome the existing challenges associated with conventional DNA library / RNA library preparation methods. These kits require less input material and are capable of generating precise DNA library / RNA libraries with minimum errors. Presently, more than 280 NGS library preparation kits are available in the market; these are compatible with a broad range of sequencing platforms, including Illumina®, Ion Torrent® and BGI NGS platforms. It is worth mentioning that over 3,200 patents related to NGS library preparation kits have been filed / granted in the past few years, demonstrating the continued innovation in this domain. Driven by the increasing demand for gene therapies and the introduction of novel and advanced NGS techniques, the NGS library preparation kits market is anticipated to witness steady growth in the coming years.


Scope of the Report



The “Next Generation Sequencing (NGS) Kits Market: Distribution by Type of Nucleotide Sequenced (DNA and RNA), Type of End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of NGS library preparation kits over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain.


Amongst other elements, the report includes:


  • A detailed assessment of the current market landscape of NGS library preparation kits, featuring information on the type of nucleotide sequenced (DNA and RNA), kit components (control total RNA / DNA, adapters, primers, enzyme mixes, buffers, RNA / DNA probes and others), quantity of sample required (less than 5 ng, 5 ng to 10 ng and more than 10 ng), turnaround time (less than 5 hours, 5 hours to 10 hours and more than 10 hours), storage temperature (deep freeze, cold and room temperature), type of sample used (purified RNA / DNA, plasma, serum, urine, cells, blood, saliva and others), kit shelf life (0.5 year and 1 year), type of sequencing (whole genome sequencing, targeted sequencing, transcriptome sequencing, RNA sequencing, ChIP sequencing, exome sequencing, bisulphite sequencing, methyl sequencing, amplicon sequencing, de novo sequencing, resequencing and shotgun sequencing) and type of sequencing platform used (Illumina, BGI, Ion Torrent, Fluidigm and Oxford Nanopore Technologies). In addition, the chapter features analysis related to NGS library preparation kit providers based on parameters, such as year of establishment, company size, location of headquarters and leading players (in terms of number of products). 
  • A competitiveness analysis of NGS library preparation kits based on various relevant parameters, namely supplier power (based on the experience of the developer) and product competitiveness (based on parameters, including type of nucleotide sequenced, kit components, quantity of sample required, turnaround time, type of sample used, kit shelf life, type of sequencing and type of sequencing platform used).
  • Elaborate profiles of prominent players offering NGS library preparation kits, based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed / granted related to NGS library preparation kits and reagents, from January 2020 to October 2021, taking into consideration parameters, such as publication year, geographical region, CPC symbols, patent focus areas, type of applicant and leading players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A case study on the history and evolution of genome sequencing with details on first, second and third generation sequencing platforms. The chapter includes information on the NGS technologies that are available till date. Further, it presents information on the various NGS service providers (industry and non-industry players) that are engaged in providing whole genome, whole exome and targeted sequencing services.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for NGS library preparation kits over the coming decade. We have provided an informed estimate on the likely evolution of the market over the period 2021-2035. The report features sales forecasts for the overall NGS library preparation kits market, wherein both the current and upcoming opportunity is segmented across [A] type of nucleotide sequenced (DNA and RNA), [B] type of end user (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.


Key Questions Answered


  • Who are the key players engaged in offering NGS library preparation kits?
  • What is the relative competitiveness of different NGS library preparation kits?
  • How is the intellectual property landscape for next generation sequencing kits likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Genome Sequencing
3.3. Types of Genome Sequencing
3.3.1. Next Generation Sequencing
3.3.1.1. Applications of Next Generation Sequencing
3.3.1.1.1. Cancer and Affiliated Biomarker Research
3.3.1.1.2. Diagnostics
3.3.1.1.3. Personalized / Precision Medicine
3.3.1.1.4. Forensics
3.3.1.2. Steps Involved in Next Generation Sequencing
3.3.1.2.1. Library Preparation
3.3.1.2.2. Amplification
3.3.1.2.3. Sequencing
3.3.1.2.4. Bioinformatics Analysis and Data Interpretation
3.3.1.3. Components of Next Generation Sequencing Kits
3.4. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Next Generation Sequencing Kits: Overall Market Landscape
4.2.1. Analysis by Type of Nucleotide Sequenced
4.2.2. Analysis by Kit Components
4.2.3. Analysis by Quantity of Sample Required
4.2.4. Analysis by Turnaround Time
4.2.5. Analysis by Storage Temperature
4.2.6. Analysis by Type of Sample Used
4.2.7. Analysis by Kit Shelf Life
4.2.8. Analysis by Type of Sequencing
4.2.9. Analysis by Type of Sequencing Platform Used
4.3. Next Generation Sequencing Kits: List of Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Products
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Methodology
5.3. Product Competitiveness Analysis: Competitive Landscape
6. COMPANY PROFILES: NEXT GENERATION SEQUENCING KITS PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Agilent Technologies
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. NGS Kit Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. BioDynami
6.3.1. Company Overview
6.3.2. NGS Kit Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Creative Biogene
6.4.1. Company Overview
6.4.2. NGS Kit Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. New England Biolabs
6.5.1. Company Overview
6.5.2. NGS Kit Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. PerkinElmer
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. NGS Kit Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Thermo Fisher Scientific
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. NGS Kit Portfolio
6.7.4. Recent Developments and Future Outlook
7. COMPANY PROFILES: NEXT GENERATION SEQUENCING KITS PROVIDERS IN EUROPE
7.1. Chapter Overview
7.2. Abcam
7.2.1 Company Overview
7.2.2. Financial Information
7.2.3. NGS Kit Portfolio
7.2.4. Recent Developments and Future Outlook
7.3. Devyser
7.3.1 Company Overview
7.3.2. NGS Kit Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Diagenode
7.4.1 Company Overview
7.4.2. NGS Kit Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Lexogen
7.5.1 Company Overview
7.5.2. NGS Kit Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. Roche
7.6.1 Company Overview
7.6.2. Financial Information
7.6.3. NGS Kit Portfolio
7.6.4. Recent Developments and Future Outlook
7.7. Tecan
7.7.1 Company Overview
7.7.2. Financial Information
7.7.3. NGS Kit Portfolio
7.7.4. Recent Developments and Future Outlook
8. COMPANY PROFILES: NEXT GENERATION SEQUENCING KITS PROVIDERS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. Enzynomics
8.2.1. Company Overview
8.2.2. NGS Kit Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. MGI
8.3.1. Company Overview
8.3.2. NGS Kit Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. Takara Bio
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. NGS Kit Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. TIANGEN Biotech
8.5.1. Company Overview
8.5.2. NGS Kit Portfolio
8.5.3. Recent Developments and Future Outlook
8.6. TransGen Biotech
8.6.1. Company Overview
8.6.2. NGS Kit Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Vazyme
8.7.1. Company Overview
8.7.2. NGS Kit Portfolio
8.7.3. Recent Developments and Future Outlook
9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Next Generation Sequencing Kits: Patent Analysis
9.3.1 Analysis by Publication Year
9.3.2. Analysis by Geography
9.3.3. Analysis by CPC Symbols
9.3.4. Emerging Focus Areas
9.3.5. Analysis by Type of Applicant
9.3.6. Leading Players: Analysis by Number of Patents
9.4. Next Generation Sequencing Kits: Patent Benchmarking
9.4.1. Analysis by Patent Characteristics
9.5. Next Generation Sequencing Kits: Patent Valuation
9.6. Leading Patents: Analysis by Number of Citations
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Next Generation Sequencing Kits Market, 2021-2035
10.3.1. Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Type of Nucleotide Sequenced
10.3.1.1. Next Generation Sequencing Kits Market for DNA, 2021-2035
10.3.1.2. Next Generation Sequencing Market for RNA, 2021-2035
10.3.2. Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Type of End User
10.3.2.1. Next Generation Sequencing Kits Market for Academic and Research Institutes, 2021-2035
10.3.2.2. Next Generation Sequencing Kits Market for Pharmaceutical and Biotechnology Companies, 2021-2035
10.3.2.3. Next Generation Sequencing Kits Market for Hospitals and Clinics, 2021-2035
10.3.2.4. Next Generation Sequencing Kits Market for Others, 2021-2035
10.3.3. Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Geography
10.3.3.1. Next Generation Sequencing Kits Market in North America, 2021-2035
10.3.3.2. Next Generation Sequencing Kits Market in Europe, 2021-2035
10.3.3.3. Next Generation Sequencing Kits Market in Asia Pacific, 2021-2035
10.3.3.4. Next Generation Sequencing Kits Market in Middle East and North Africa, 2021-2035
10.3.3.5. Next Generation Sequencing Kits Market in Latin America, 2021-2035
10.3.3.6. Next Generation Sequencing Kits Market in Rest of the World, 2021-2035
11. CASE STUDY: NEXT GENERATION SEQUENCING TECHNOLOGIES AND SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Historical Evolution of Genome Sequencing
11.2.1. First Generation DNA Sequencers
11.2.2. Second Generation HT-NGS Platforms
11.2.3. Third Generation HT-NGS Platforms
11.2.3.1. Heliscope Single Molecule Sequencer
11.2.3.2. Single Molecule Real Time Sequencer
11.2.3.3. Single Molecule Real Time (RNAP) Sequencer
11.2.3.4. Nanopore DNA Sequencer
11.2.3.5. Multiplex Polony Technology
11.2.3.6. The Ion Torrent Sequencing Technology
11.2.4. Comparison of First, Second and Third Generation technologies
11.3. Next Generation Sequencing Technologies
11.3.1. Analysis by Type of Application
11.4. Next Generation Sequencing Service Providers
11.4.1. Next Generation Sequencing Service Providers: Industry Players
11.4.2. Analysis by Year of Establishment
11.4.3. Analysis by Company Size
11.4.4. Analysis by Location of Headquarters
11.4.5. Analysis by Type of Service Offered
11.5. Next Generation Sequencing Service Providers: Non-Industry Players
11.5.1. Analysis by Year of Establishment
11.5.2. Analysis by Location of Headquarters
11.5.3. Analysis by Type of Service Offered
12. CONCLUDING REMARKS
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Tecan
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Len Goren, General Manager
14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:


  • 10x Genomics
  • 1st BASE
  • Abcam
  • ABclonal 
  • Advanced Biological Laboratories (ABL)
  • Active Motif
  • Admera Health
  • Agendia
  • Agilent Technologies
  • Agiomix
  • AgriGenome Labs 
  • Almac Group
  • Annoroad Gene Technology
  • ANTISEL
  • Applied Biological Materials (abm)
  • Arizona Genomics Institute
  • Auragen
  • Australian Genome Research Facility (AGRF)
  • BD
  • BGI Genomics
  • BioChain
  • BioDynami
  • Biofidal
  • Bio-Rad
  • Biosearch Technologies (Acquired by LGC)
  • Brigham and Women's Hospital
  • Brigham Young University
  • Broad Institute
  • CD Genomics
  • CeGaT
  • Cellecta
  • CEN4GEN
  • CENTOGENE
  • Centre for Cellular and Molecular Platforms (C-CAMP)
  • Children's Hospital of Philadelphia
  • City of Hope
  • Claret Bioscience
  • Cold Spring Harbor Laboratory
  • Columbia Genome Center
  • Creative Biogene
  • Dana-Farber Cancer Institute
  • Dante Labs
  • De Novo Genomics
  • Devyser
  • DiaCarta
  • Diagenode (Acquired by Hologic)
  • Diagnomics
  • Diversigen
  • DNA Genotek
  • DNA Link
  • DNAVision
  • Durham University
  • Earlham Institute
  • Eclipse Bioinnovations
  • Edinburgh Genomics
  • Enzo Life Sciences
  • Enzynomics
  • EpiGentek
  • Eurofins Genomics
  • Fasteris
  • Firalis 
  • Fluidigm
  • Fulgent Genetics
  • Full Genomes Corporation (FGC)
  • Garvan Institute of Medical Research
  • Genapsys
  • Gencove
  • Gene by Gene
  • GeneFirst
  • GENEWIZ
  • Genome.One
  • GenomeScan
  • GenomeStream
  • Genomics Personalized Health
  • Genomix4Life
  • Genosity
  • Genotypic Technology
  • GenScript
  • Genuity Science (Previously known as WuXi NextCODE)
  • GenXPro
  • Guardant Health
  • Harvard College
  • HistoGenetics
  • Integrated DNA Technologies
  • Illinois Institute of Technology
  • Illumina
  • Immatics Biotechnologies
  • Intact Genomics
  • Johns Hopkins University
  • Leland Stanford Junior University
  • Lexogen 
  • LGC
  • Loop Genomics
  • Lucigen (Acquired by LGC)
  • Macrogen
  • MagBio Genomics
  • Maryland Genomics
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Massey University
  • Mass General Brigham (Previously known as Partners HealthCare)
  • Max Planck Institute 
  • McGill University
  • Molecular Cloning Laboratories (MCLAB)
  • MedGenome
  • Merck
  • MGI
  • Microsynth
  • MNG Laboratories (Acquired by LabCorp)
  • MOgene
  • myGenomics
  • Natera
  • National Institute of Health and Medical Research (INSERM)
  • National Instrumentation Center for Environmental Management
  • New England Biolabs (NEB)
  • New York Genome Center (NYGC)
  • NimaGen
  • Norgen Biotek
  • Novogene 
  • Nucleome Informatics
  • OGT
  • Oklahoma Medical Research Foundation (OMRF)
  • Omega Bioservices
  • Otogenetics
  • Oxford Nanopore Technologies
  • Pacific Biosciences (PacBio)
  • PerkinElmer 
  • Phalanx Biotech 
  • Psomagen
  • Q2 Solutions
  • QIAGEN
  • Quantabio
  • Quick Biology
  • Rapid Genomics
  • RealSeq Biosciences
  • REPROCELL
  • Roche
  • RTL Genomics
  • SeqLL
  • SeqMatic
  • Shanghai Oe Biotech
  • Source BioScience
  • Stanford University
  • StarSEQ
  • Swift Biosciences (Acquired by IDT)
  • System Biosciences (SBI)
  • Takara Bio
  • Tecan
  • Tempus
  • Texas A&M AgriLife
  • The Sequencing Center
  • Theragen Etex
  • Thermo Fisher Scientific
  • The University of Edinburgh
  • TIANGEN Biotech
  • TransGen Biotech
  • TriLink BioTechnologies
  • Twist Bioscience
  • UCLA Health
  • University of California
  • University of Delaware
  • University of Leeds
  • University of Liverpool
  • University of Maryland
  • University of Minnesota
  • University of Oxford 
  • University of Texas
  • University of Washington
  • University of Wisconsin
  • University of Zurich
  • UNSW Sydney
  • Uppsala University
  • Vazyme Biotech
  • Veritas
  • Verogen
  • Waksman Institute of Microbiology (Rutgers University)
  • Washington State University
  • Washington University
  • Wuhan Fraser Gene Information 
  • Xcelris Genomics
  • Yaazh Xenomics
  • Yale School of Medicine
  • YouSeq
  • Zymo Research

Methodology

 

 

Loading
LOADING...